SNGX

Soligenix, Inc.

Soligenix, Inc. (SNGX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.3
EV / EBITDA 0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -15.8%
Price Return 12M -76.5%
Catalyst Signal 0.00
Market Cap $7.5M
TTM Revenue N/A
Price / Sales N/A
ROE -127.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B+ (3.7) C+ (2.5) D+ (1.6) C (2.5) C+ (2.6) C+ (2.6)
2026-11-08 A- (3.9) C+ (2.5) D- (0.9) C+ (2.8) C+ (2.6) C+ (2.6)
2026-11-01 B+ (3.7) C (2.5) D- (1.0) C+ (2.6) C+ (2.7) C (2.5)
2026-10-25 B+ (3.7) C (2.4) D- (1.0) D+ (1.8) C+ (2.6) C (2.3)
2026-10-18 B+ (3.7) C (2.4) D- (1.0) D+ (1.7) C+ (2.6) C (2.3)
Page 1 of 4